GSK - INTERIM EFFICACY AND SAFETY DATA FOR BLENREP AS A FIRST LINE TREATMENT ARE EXPECTED IN EARLY 2028 (The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
